• Small Molecules
    • Biologics
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Emerging Biopharma
      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers

Blogs

Choose from a variety of resources to get a better understanding of Syngene’s point of view, expertise or approach to drug discovery, development and manufacturing to ensure client success.

Solving Prep-HPLC Challenges in Early Drug Discovery: Efficient Purification of Unstable Prodrugs via C18 SPE
In the fast-paced world of drug discovery, every day counts—and so does every drop of solvent. Yet for chemists working with polar, unstable prodrugs and new chemical entities (NCEs), one critical step has remained frustratingly slow, expensive, and inefficient: purification.
17th Jul, 2025
From Fragile to Agile: Strategic imperatives for strengthening biopharma supply chains
In today’s rapidly evolving world, a resilient supply chain is no longer optional for the biopharma industry; it’s a strategic necessity.
10th Jul, 2025
Overcoming ADME Challenges in PROTAC Development: Key Insights from Syngene Experts
Targeted protein degraders like PROTACs offer novel therapeutic potential but face ADME hurdles—poor solubility, permeability, and weak IVIVC. Experts Prasoon Chaturvedi (C4 Therapeutics), Vishwottam Kandikere, and Amol Raje (Syngene) discussed solutions.
27th Jun, 2025
Bridging the Unbridgeable: The Promise of PROTACs in Drug Discovery
Imagine a world where diseases once deemed “undruggable” are met with targeted, precise therapies. This vision is rapidly becoming a reality, thanks to the revolutionary technology of PROTACs (proteolysis-targeting chimeras).
27th Jun, 2025
Paws, Pills and Progress - CRDMO’s pivotal role
As I stepped into the conference hall in Boston, I overheard an investor say, “The next billion-dollar biotech might just come from the animal health sector.
26th Jun, 2025
Reducing variability in gene expression: Bottlenecks and Solutions
Explore challenges in reducing the variability in gene expression in traditional cell line development (CLD) and the power of the transposon system to address these inefficiencies.
23rd Jan, 2025
Quantifying a biomarker in mice brain for treating mood and anxiety disorders
A robust LC-MS-based quantitative method developed at Syngene to measure biomarker 2-AG in mice brain tissues for treating mood and anxiety disorders.
18th Oct, 2024
Risk assessment strategy for nitrosamine drug substance-related impurities
The potential causes of nitrosamine drug substance-related impurities and Syngene’s strategic framework for identification and management of these impurities to meet regulatory guidelines for product safety.
2nd Sep, 2024
Innovation at Syngene: Translatable models for improving cancer research
Syngene has developed orthotopic models validated against the standard of care and tumor models with 3D culture, which can help improve translatability and clinical relevance in cancer research.
12th Jun, 2024
pDNA and mRNA manufacturing in the age of Precision Therapies: The role of CDMOs
Challenges in pDNA manufacturing and why CDMOs are best suited for supplying pDNA for Precision Therapies.
28th Nov, 2023

To view or email, Please share your details view

Your browser does not support this function.

To download, Please share your details

To view or email, Please share your details view

To download, Please share your details